Enliven Therapeutics, Inc. ($ELVN)
Filing Information
| Accession Number | 0001882764-26-000008 |
|---|---|
| Form Type | 4 |
| Filing Date | Sep 21, 2026 |
| Document | View SEC Filing |
Transactions
5
Total Shares
13,982
Total Value
$362,135.71
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CHIEF FINANCIAL OFFICER | Common Stock | โ | Sep 17, 2026 | Exercise/Conversion | 3,982 | $14.85 | $59,132.70 | 44,018 | Direct | โ | View Details | |
CHIEF FINANCIAL OFFICER | Common Stock | โ | Sep 17, 2026 | Sale | 3,535 | $50.03 | $176,851.10 | 40,483 | Direct | โ | View Details | |
CHIEF FINANCIAL OFFICER | Common Stock | โ | Sep 17, 2026 | Sale | 2,194 | $50.72 | $111,270.47 | 38,289 | Direct | โ | View Details | |
CHIEF FINANCIAL OFFICER | Common Stock | โ | Sep 17, 2026 | Sale | 289 | $51.49 | $14,881.45 | 38,000 | Direct | โ | View Details | |
CHIEF FINANCIAL OFFICER | Stock Option (right to buy) | Derivative | Sep 17, 2026 | Exercise/Conversion | 3,982 | $0.00 | $0.00 | 181,018 | Direct | โ | View Details |